Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background Patients with early-stage breast cancer receiving docetaxel and cyclophosphamide chemotherapy have a risk of severe neutropenia and febrile neutropenia. The National Comprehensive Cancer Network recommends GCSF to reduce the risk of febrile neutropenia. Eflapegrastim—a novel, long-acting, recombinant human GCSF linked to human IgG4 Fc fragment—showed improved bone marrow residence vs pegfilgrastim that may allow for same-day dosing.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
